Cipla Ltd

Total revenue from operations marginally rose 0.02% to Rs 7,074.48 crore in Q3 FY26 as against Rs 7,072.97 crore in Q3 FY25. Profit before exceptional items and tax were at Rs 1,169.02 crore in Q3 FY26, down 38.98% as against Rs 1,916.09 crore in Q3 FY25. The company reported exceptional loss of Rs 275.91 crore in Q3 FY26. EBITDA declined 36.9% to Rs 1,255 crore in Q3 FY26, as against Rs 1,989 crore reported in Q3 FY25. The EBITDA margin remained stable at 17.7%. The company's One-India business reported a strong 10% year-on-year growth in Q3, driven by improved performance across key segments. The company's chronic portfolio share increased to 62.3%, reflecting a healthier product mix in the market. The North America business reported quarterly revenue of $167 million. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, commanding a 22% market share. The FY27 pipeline includes four major respiratory launches, including gAdvair. During the quarter, the business launched gVictoza and expects to introduce three more peptide assets in FY27, with three of the four respiratory assets filed from U.S. facilities. In the South African private market, the company posted secondary growth of 6.3%, ahead of the market's 5.7% growth, with its prescription business retaining the No. 2 position. In Emerging Markets and Europe, the company's focused market strategy drove 7% year-on-year growth in USD terms, supported by strong performance across both DTM and B2B segments. The company's R&D investments stood at Rs 494 crore, representing 7% of sales and marking a 37.4% year-on-year increase, driven by higher product filings and ongoing development initiatives. The firm maintained a strong net cash position of Rs 10,229 crore, with debt largely comprising lease liabilities. Umang Vohra and Achin Gupta, MD and Global CEO, Cipla, said the company continues to make solid progress across its key markets. Global revenues for Q3FY26 stood at INR 7,074 crore, despite a decline in gRevlimid sales. The OneIndia business grew 10% YoY, while the Branded Prescription segment delivered double-digit growth, led by key therapies outpacing the market. Trade Generics posted healthy gains, and Anchor brands in the Consumer Health Business maintained their leadership position. The US business recorded revenue of $167 million, with upcoming launches expected to offset the gRevlimid decline and drive long-term growth. In South Africa, the private business continued to outperform the market, while Emerging Markets and Europe grew 7% YoY in USD terms, driven by a focused market strategy. Looking ahead, Cipla said it will focus on expanding key markets, strengthening flagship brands, investing in its pipeline, and resolving regulatory matters. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. Powered by Capital Market - Live

Net profit of Cipla declined 56.97% to Rs 675.80 crore in the quarter ended December 2025 as against Rs 1570.51 crore during the previous quarter ended December 2024. Sales rose 0.02% to Rs 6962.97 crore in the quarter ended December 2025 as against Rs 6961.60 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales6962.976961.60 0 OPM %18.0228.57 - PBDT1447.372195.89 -34 PBT1169.021916.09 -39 NP675.801570.51 -57 Powered by Capital Market - Live

Cipla Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1389.6, down 0.57% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.61% on the day, quoting at 25538.45. The Sensex is at 83093.05, down 0.57%.Cipla Ltd has lost around 8.15% in last one month.Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has eased around 3.39% in last one month and is currently quoting at 22217.05, down 0.3% on the day. The volume in the stock stood at 11.27 lakh shares today, compared to the daily average of 17.66 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1391, down 0.42% on the day. Cipla Ltd tumbled 3.86% in last one year as compared to a 9.4% rally in NIFTY and a 0.15% fall in the Nifty Pharma index.The PE of the stock is 21.72 based on TTM earnings ending September 25.Powered by Capital Market - Live

Mahindra & Mahindra Financial Services Ltd, CSB Bank Ltd, ZF Commercial Vehicle Control System India Ltd and Allied Blenders & Distillers Ltd are among the other losers in the BSE's 'A' group today, 07 January 2026.Cipla Ltd lost 4.26% to Rs 1465.2 at 14:45 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 3.55 lakh shares were traded on the counter so far as against the average daily volumes of 95734 shares in the past one month.Mahindra & Mahindra Financial Services Ltd tumbled 4.14% to Rs 358.95. The stock was the second biggest loser in 'A' group.On the BSE, 3.72 lakh shares were traded on the counter so far as against the average daily volumes of 2.09 lakh shares in the past one month.CSB Bank Ltd crashed 3.54% to Rs 517.2. The stock was the third biggest loser in 'A' group.On the BSE, 57791 shares were traded on the counter so far as against the average daily volumes of 86720 shares in the past one month.ZF Commercial Vehicle Control System India Ltd pared 3.48% to Rs 14750.2. The stock was the fourth biggest loser in 'A' group.On the BSE, 677 shares were traded on the counter so far as against the average daily volumes of 754 shares in the past one month.Allied Blenders & Distillers Ltd corrected 3.47% to Rs 532.15. The stock was the fifth biggest loser in 'A' group.On the BSE, 65307 shares were traded on the counter so far as against the average daily volumes of 25511 shares in the past one month.Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live

Cipla announced that NSE Sustainability Ratings & Analytics, a SEBI registered ESG Rating Provider (NSE Sustainability), has independently assigned the Environmental, Social, and Governance (ESG) Rating of 66 to the Company for FY 2024-25Powered by Capital Market - Live

Cipla Ltd is up for a fifth straight session today. The stock is quoting at Rs 1524.9, up 0.37% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.28% on the day, quoting at 25949.3. The Sensex is at 84711.84, up 0.29%. Cipla Ltd has slipped around 1.77% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has slipped around 3.33% in last one month and is currently quoting at 22593.4, up 0.8% on the day. The volume in the stock stood at 6.08 lakh shares today, compared to the daily average of 17 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1531.3, up 0.45% on the day. Cipla Ltd is up 1.68% in last one year as compared to a 10.27% jump in NIFTY and a 4.7% jump in the Nifty Pharma index.The PE of the stock is 23.62 based on TTM earnings ending September 25.Powered by Capital Market - Live

The stock has fallen 4.55% in two trading sessions since the announcement. On a consolidated basis, the drug major reported a 3.7% increase in net profit to Rs 1,353.37 crore on a 7.6% rise in total revenue from operations to Rs 7,589.44 crore in Q2 FY26 over Q2 FY25. Profit before tax (PBT) stood at Rs 1,853.53 crore in Q2 FY26, marking a 3.6% increase from Rs 1,789.06 crore reported in the same quarter last year. EBITDA rose 0.5% to Rs 1,895 crore in Q2 FY26, as against Rs 1,886 crore reported in Q2 FY25. The EBITDA margin stood at 25% in Q2 FY26. The company's One India Business reported a 7% year-on-year growth for the quarter. The overall chronic portfolio mix in the domestic market improved to 61.8%. In North America, Cipla reported quarterly revenue of $233 million, supported by traction in differentiated assets. The One Africa region continued its growth momentum, recording a 5% YoY increase in revenue (USD terms). Cipla's prescription business ranked No. 2 in the market. Emerging Markets and Europe also performed well, registering a healthy 15% YoY revenue growth in USD terms. The company's R&D investments stood at Rs 539 crore, accounting for 7.1% of sales, driven by product filings and development efforts. The company reported a strong net cash position of Rs 9,901 crore. The company's debt primarily comprises lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO, Cipla, said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY26, we delivered our highest-ever quarterly revenue of INR 7,589 Cr, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets. Our One-India business grew at 7% YoY. Key therapies in the branded prescription business continued to deliver strong market growth, and with the launch of Yurpeak (Tirzepatide), we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly. Trade Generics recorded double-digit growth, and Anchor brands of the Consumer Health Business maintained their leadership position. With positive traction in our differentiated assets, the US business posted a revenue of $233 million during the quarter. In Q3 FY26, gRevlimid is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realized. In One Africa, we achieved a healthy growth of 5% YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15% YoY in USD terms on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, and investing in the future pipeline, as well as focusing on resolutions on the regulatory front.' In addition to the results, Cipla announced that its MD and Global CEO, Umang Vohra, will not seek reappointment. The company further stated that Achin Gupta, its current Global COO, will take over as CEO for a five-year term starting 1 April 2026. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.Powered by Capital Market - Live

Net profit of Cipla rose 3.73% to Rs 1351.17 crore in the quarter ended September 2025 as against Rs 1302.53 crore during the previous quarter ended September 2024. Sales rose 6.98% to Rs 7447.42 crore in the quarter ended September 2025 as against Rs 6961.22 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales7447.426961.22 7 OPM %25.4427.09 - PBDT2150.522060.80 4 PBT1853.531789.06 4 NP1351.171302.53 4 Powered by Capital Market - Live

'The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla furthers Lilly's commitment to expanding access to innovative treatments for chronic conditions,' said Winselow Tucker, President and General Manager, Lilly India. 'Our mission'to make life better for people around the world'drives our commitment to accelerate the introduction of innovative medicines and expand access to hard-to-reach communities. With India facing a growing burden of type 2 diabetes and obesity, broader availability of Tirzepatide will ensure that more patients can benefit from this innovative therapy,' he added. Lilly will manufacture and supply Yurpeak to Cipla, while Cipla will distribute and promote the brand across India. The product will be priced the same as Mounjaro, Lilly's existing Tirzepatide brand. Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, prescribed as an adjunct to diet and exercise for type 2 diabetes and chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Yurpeak will be available in the KwikPen presentation a multi-dose, single-patient-use prefilled pen with four fixed doses, administered once weekly. The pen will be offered in six dose strengths ' 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg ' allowing healthcare professionals to tailor treatment plans for individual patient needs. Achin Gupta, global chief operating officer, Cipla, added, 'At Cipla, we remain steadfast in our commitment to advancing patient care by facilitating access to the best of global scientific innovation. With the introduction of Yurpeak (Tirzepatide), we are stepping into obesity care with the same commitment and scale that have defined our efforts in respiratory and chronic therapies.' Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. Cipla reported 10.18% increase in consolidated net profit to Rs 1,297.62 crore on a 3.93% rise in total revenue from operations to Rs 6,957.47 crore in Q1 FY26 over Q1 FY25. Shares of Cipla slipped 3.16% to currently trade at Rs 1,593.20 on the BSE. Powered by Capital Market - Live